Ac-(HHPHG)4 -NH2
General Information
DRACP ID DRACP00111
Peptide Name Ac-(HHPHG)4 -NH2
Sequence HHPHGHHPHGHHPHGHHPHG
Sequence Length 20
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP Cancer targeted peptides Antiangiogenic
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
3LL | Lewis lung carcinoma | Carcinoma | The 50 mg/kg dose in the 3LL model significantly inhibited tumor growth by 48% | Syngeneic tumor models | Not available | 1 |
B16-F1 | Mouse melanoma | Carcinoma | The 50 mg/kg dose in the 3LL model significantly inhibited tumor growth by 48% | Syngeneic tumor models | Not available | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Tropomyosin
Affinity Not available
Mechanism Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Acetylation
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C100H126N44O21
Absent amino acids ACDEFIKLMNQRSTVWY
Common amino acids H
Mass 261948
Pl 8.15
Basic residues 12
Acidic residues 0
Hydrophobic residues 0
Net charge 12
Boman Index -5216
Hydrophobicity -232
Aliphatic Index 0
Half Life
Mammalian: 1.1 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 4
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 15313924
Title Peptides derived from the histidine-proline domain of the histidine-proline-rich glycoprotein bind to tropomyosin and have antiangiogenic and antitumor activities
Doi 10.1158/0008-5472.CAN-04-0440
Year 2004
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available